The Dutch ME/CFS Cohort and Biobank consortium
NMCB is a collaboration of Dutch research institutes, medical centres and patient organisations dedicated to biomedical research of
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
This project is made possible by:
What is ME/CFS?
ME/CFS
ME/CFS is a serious disease that disrupts patients’ lives and causes a lot of suffering. ME/CFS patients experience continuous and intense exhaustion. In addition, symptoms worsen even after minimal mental, physical, emotional or social exertion – something known as “post-exertional malaise” (PEM).
ME/CFS symptoms:
- Post-exertional malaise (PEM)
- Muscle pain, headache
- Disturbed sleep
- Sensitivity to stimuli (light, sounds, touch or smells)
- Overall state of discomfort and illness
- Cognitive problems, such as problems with information processing, concentration and memory
WHAT WILL NMCB DO?
Building an international ME/CFS hub
Biomedical research
Despite the impact of ME/CFS, much is still unknown about its causes and possible treatments. NMCB recognises the need for biomedical research on ME/CFS. By establishing a national patient cohort and biobank, we are building an international infrastructure for research to improve the knowledge, diagnosis and treatment of ME/CFS.
NMCB research
In an eight-year collaboration between scientific and clinical experts, as well as patients, the NMCB will enable in-depth research divided first of all into six subprojects. In collaboration with an international research network, the NMCB will establish an international ME/CFS hub to facilitate additional research on ME/CFS.
Collaborations
Patient representatives
Patients and their experiences are an essential part of the NMCB. In collaboration with three ME/CFS patient organisations, we want to ensure that patients’ experiences remain central to our studies.
- News
26/08/2024
- News
12/05/2024
Get in Touch
Contacts
Do you have any questions about the NMCB? Feel free to reach out using the form below, or find your question at the FAQ page.